T-cells from the liver and lymph nodes show promising potential for future treatments of liver cancer, according to a new ...

Opdivo plus Yervoy shows efficacy and manageable safety as first-line treatment for unresectable hepatocellular carcinoma in ...

Patients with metabolic dysfunction-associated steotohepatitis (MASH) who are already taking a glucagon-like peptide-1 ...

SGLT-2 inhibitors vs DPP-4 inhibitors were associated with a reduced risk for liver cirrhosis among patients with type 2 diabetes.

Researchers identified the enzyme CMPK2 as a possible target for therapies aiming to prevent metabolic dysfunction-associated ...

Adding camrelizumab and rivoceranib to TACE improved PFS in patients with unresectable HCC in a phase 2 trial.

This alarming trend underscores the need for greater awareness and effective risk stratification strategies to manage the growing burden of this disease. In addition to NAFLD, hepatocellular ...

Analysis of gut and mucosal microbiomes in patients with extrahepatic cholangiocarcinoma.

Adding camrelizumab and rivoceranib to transarterial chemoembolization (TACE) significantly prolonged progression-free ...

Normothermic machine perfusion (NMP) to preserve livers prior to transplant was associated with significantly improved ...

Can-Fite BioPharma has secured a US patent for Namodenoson, its lead drug candidate, for use as an anti-obesity treatment.

Discover how alcohol consumption exacerbates the risk of cirrhosis and hepatocellular carcinoma by promoting hepatitis B ...